Telix partners with EDAP and Profound on prostate imaging tech

Telix Pharmaceuticals Limited (NASDAQ: TLX) announced it entered letters of intent with EDAP TMS S.A. (NASDAQ: EDAP) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN) to explore collaborations involving PSMA-PET imaging in prostate cancer treatment approaches.

The partnerships will investigate the use of Telix's PSMA-PET imaging agents Gozellix and Illuccix alongside robotic high-intensity focused ultrasound and transurethral ultrasound ablation technologies for treating localized prostate cancer. The collaborations aim to explore patient selection, treatment planning and post-treatment monitoring applications.

EDAP develops robotic energy-based therapies including the Focal One platform for prostate focal therapy. Profound Medical operates the TULSA-PRO platform, which enables MRI-guided prostate ablation procedures. Both companies focus on minimally invasive treatments designed to preserve healthy tissue while treating cancer.

The collaborative activities will concentrate on scientific, educational and research engagement rather than promotional activities, according to the announcement made May 15. PSMA-PET imaging is not currently approved for specific treatment-planning indications associated with these emerging therapies.

Telix's PSMA-PET imaging agents are designed to detect prostate-specific membrane antigen, which is expressed in prostate cancer cells. The company operates globally with headquarters in Melbourne, Australia, and maintains operations in the United States, United Kingdom, Brazil, Canada, Europe and Japan.

You May Also Be Interested In

• Fuerte changes name to Talamore Mining, shares to trade as TALA
• ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026
• TEN Holdings (XHLD) files for 8M share offering